SEC Comment Letter 0000000000-23-008833 to Pharvaris N.V. (PHVS)
Pharvaris N.V.
Date: Aug. 14, 2023 · CIK: 0001830487 · Accession: 0000000000-23-008833
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273757
Letter
United States securities and exchange commission logo August 14, 2023 Berndt Modig Chief Executive Officer Pharvaris N.V. Emmy Noetherweg 2 2333 BK Leiden Re:Pharvaris N.V. Registration Statement on Form F-3 Filed August 7, 2023 File No. 333-273757 Dear Berndt Modig: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Lee, Esq.
Show Raw Text
United States securities and exchange commission logo
August 14, 2023
Berndt Modig
Chief Executive Officer
Pharvaris N.V.
Emmy Noetherweg 2
2333 BK Leiden
Re:Pharvaris N.V.
Registration Statement on Form F-3
Filed August 7, 2023
File No. 333-273757
Dear Berndt Modig:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jennifer Lee, Esq.